News for Healthier Living

AACR: Topical gel relieves painful skin rash side effect caused by targeted therapy for colorectal cancer

(mid dot) LUT014, a topical BRAF inhibitor made by Lutris Pharma, is the first agent to treat the cause of the rash without interfering with the treatment itself (mid dot) Over two-thirds of patients had successful treatment with the higher dose of LUT014 compared to one-third with placebo

April 27, 2025


April 29 2025

April 28 2025

April 27 2025

April 26 2025

April 25 2025

April 24 2025

April 23 2025

April 22 2025

April 21 2025

April 19 2025

April 18 2025

April 17 2025

April 16 2025

April 15 2025